Humacyte Inc [HUMA] stock is trading at $1.43, down -2.05%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The HUMA shares have lost -9.49% over the last week, with a monthly amount drifted -35.29%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Humacyte Inc [NASDAQ: HUMA] stock has seen the most recent analyst activity on August 27, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $3.50. On December 20, 2024, H.C. Wainwright reiterated its Buy rating and revised its price target to $15 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $6 on December 11, 2023. Piper Sandler upgraded its rating to a Neutral and raised its price target to $3.50 on August 14, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on June 22, 2023, and assigned it a price target of $6. In a note dated May 16, 2022, Piper Sandler downgraded an Underweight rating on this stock and revised its target price from $10 to $4.
Humacyte Inc [HUMA] stock has fluctuated between $1.15 and $6.77 over the past year. Currently, Wall Street analysts expect the stock to reach $3.5 within the next 12 months. Humacyte Inc [NASDAQ: HUMA] shares were valued at $1.43 at the most recent close of the market. An investor can expect a potential return of 144.76% based on the average HUMA price forecast.
Analyzing the HUMA fundamentals
Gross Profit Margin for this corporation currently stands at 0.05% with Operating Profit Margin at -13.82%, Pretax Profit Margin comes in at -7.29%, and Net Profit Margin reading is -7.29%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is 3.08 and Total Capital is -0.94. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 3.73.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3833 points at the first support level, and at 1.3367 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4733, and for the 2nd resistance point, it is at 1.5167.
Ratios To Look Out For
For context, Humacyte Inc’s Current Ratio is 2.45. In addition, the Quick Ratio stands at 1.93 and the Cash Ratio stands at 1.8. Considering the valuation of this stock, the price to sales ratio is 276.18, the price to book ratio is 55.17.
Transactions by insiders
Recent insider trading involved Dougan Brady W, Director, that happened on Aug 19 ’25 when 1.1 million shares were sold. Director, Dougan Brady W completed a deal on Aug 18 ’25 to sell 0.55 million shares. Meanwhile, Director Dougan Brady W sold 0.59 million shares on Aug 20 ’25.
